2024
DOI: 10.1001/jamaneurol.2024.0395
|View full text |Cite
|
Sign up to set email alerts
|

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS

Guillaume Jouvenot,
Guilhem Courbon,
Mathilde Lefort
et al.

Abstract: ImportanceA recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.ObjectiveTo determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increase… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
references
References 58 publications
0
0
0
Order By: Relevance